Engaging talented leaders is an issue facing the biotech industry in almost any life sciences cluster you care to look. At the executive level competition for CEOs, R&D, Finance, Medical and BD executives is fierce, but equally so at the board level, the search for talent is far-reaching. This search for talent is acutely felt in Cambridge, Massachusetts, where Kendall Square has become a battle ground for high caliber leaders, spilling out to companies throughout the wider Boston and Massachusetts vicinity.
Immunocore, a biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, has appointed James Sandy as Chief Development Officer and Julian Hirst as Director of Corporate Finance. These new positions will be based in the firm’s headquarter in Oxford, UK.
Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ based in Cambridge, Mass, has appointed Elizabeth (Betsy) Nabel to its Board of Directors. Nable is the President of Harvard-affiliated Brigham and Women’s Health Care (BWHC) and a Professor of Medicine at Harvard Medical School.
Gurnet Point Capital, a Cambridge, MA-based US healthcare and life sciences investment firm, has founded Boston Pharmaceuticals, a fully integrated drug development company with a $600 million commitment. Christopher Viehbacher, the Managing Partner of Gurnet Point Capital and the former CEO of Sanofi, was appointed as Boston Pharmaceuticals’ Chairman. Robert Armstrong, the former head of external R&D at Chorus (Eli Lilly), was named CEO.
Author: Anjie Cai Anderson
These are the 5 articles most viewed this year…so here is a recap for your to dive back in and read what you missed.